University of Montana

ScholarWorks at University of Montana
Graduate Student Theses, Dissertations, &
Professional Papers

Graduate School

2016

DEVELOPMENT OF REPLICATION-COMPETENT VSV-BASED
VACCINES FOR PROTECTION AGAINST HANTAVIRUSES
Joshua Ovila Marceau

Follow this and additional works at: https://scholarworks.umt.edu/etd

Let us know how access to this document benefits you.
Recommended Citation
Marceau, Joshua Ovila, "DEVELOPMENT OF REPLICATION-COMPETENT VSV-BASED VACCINES FOR
PROTECTION AGAINST HANTAVIRUSES" (2016). Graduate Student Theses, Dissertations, & Professional
Papers. 10899.
https://scholarworks.umt.edu/etd/10899

This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of
Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an
authorized administrator of ScholarWorks at University of Montana. For more information, please contact
scholarworks@mso.umt.edu.

DEVELOPMENT OF REPLICATION-COMPETENT VSV-BASED VACCINES
FOR PROTECTION AGAINST HANTAVIRUSES
By
JOSHUA OVILA MARCEAU
Bachelor of Science in Microbiology, Pennsylvania State University, State College,
Pennsylvania, 2009
Previous Degree, College or University, City, State or Country, Year
Dissertation
presented in partial fulfillment of the requirements
for the degree of
Doctor of Philosophy in Biomedical Sciences
The University of Montana
Missoula, MT
December 2016
Approved by:
Scott Whittenburg, Dean of The Graduate School
Graduate School
Dr. Heinz Feldmann, Co-Chair
Primary Research Advisor
NIH NIAID Rocky Mountain Laboratories
Hamilton, Montana USA 59840
Dr. Keith Parker, Professor (Co-Chair)
Department of Biomedical Sciences
Dr. Ruben M. Ceballos, Assistant Professor
Department of Biological Sciences
University of Arkansas
Fayetteville, Arkansas, USA 72730
Dr. Brent Ryckman, Associate Professor,
Division of Biological Sciences
Dr. Scott Wetzel, Associate Professor,
Division of Biological Sciences

Marceau, Joshua O., Ph.D., Fall 2016

Department of Biomedical Sciences

DEVELOPMENT OF REPLICATION-COMPETENT VSV-BASED VACCINES
FOR PROTECTION AGAINST HANTAVIRUS INFECTION

Co-Chairperson: Dr. Keith Parker
Co-Chairperson: Heinz Feldmann
Abstract:
This study looks at the effects of the position and numbers of foreign
immunogens in the vesicular stomatitis virus (VSV) genome on vector
attenuation and vaccine efficacy. To generate the recombinant vaccine vectors, a
VSV Indiana strain was modified by removing the native VSV glycoprotein and
replacing it with one or two foreign glycoproteins; one derived from the filovirus
Zaire ebolavirus (ZEBOVgp) and the other from the hantavirus Andes virus
(ANDVgpc). Two monovalent (rVSVΔG-ANDVgpc and rVSVΔG-ZEBOVgp) and
two bivalent (rVSVΔG-ANDVgpc-ZEBOVgp and rVSVΔG-ZEBOVgp-ANDVgpc
recombinant vectors were compared. All vectors were attenuated in cell culture
and in immunocompetent hamsters when compared to rVSV wildtype (rVSVwt).
rVSVΔG-ZEBOVgp and other unrelated monovalent rVSV vectors did show
pathogenicity in an immunocompromised mouse model making this model
unsuitable for vaccine efficacy testing. rVSV vaccine vector efficacy testing was
explored in the established lethal ANDV hamster model. In addition, two routes of
immunization, intraperitoneal and intranasal, were compared. The two bivalent
vectors both mediated full protection when administered even 3 days prior to
ANDV challenge independent of the route of immunization. The monovalent
rVSVΔG-ANDVgpc was similarly protective but intranasal immunization showed
reduced efficacy when administered close to challenge. The bivalent rVSVΔGZEBOVgp-ANDVgpc was most potent in post-exposure treatment, followed by
the monovalent rVSVΔG-ZEBOVgp. The monovalent rVSVΔG-ANDVgpc was
least potent in post-exposure treatment. Intraperitoneal immunization was
superior over the intranasal route in post-exposure treatment. Our data indicates
the benefit of bivalent rVSV vaccine vectors based on the rVSVΔG-ZEBOVgp
backbone with the second immunogen expressed in the downstream position in
peri-exposure application.
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PRELUDE

In this dissertation, ongoing work toward developing replicationcompetent viral-based vaccines against a selected hantavirus is described.
In Chapter 1, an introduction to hantaviruses, their biogeography and life
cycle, and the zoonotic human diseases that they cause is provided. This is
followed by an introduction to Vesicular Stomatitis Virus (VSV) which is
commonly used as an experimental vaccine platform. The chapter concludes
with an overview of the core problem or “scientific question” addressed as part of
the work that is presented in subsequent chapters of the thesis.
In Chapter 2, an expanded discussion on the advantages and
disadvantages, benefits and limitations of employing a rVSV platform for vaccine
development against deadly negative single-strand RNA (–ssRNA) viruses is
provided. This chapter is based on work completed in 2009-2015 and recently
published (October, 2015). Specifically, the efficacy of rVSV-based vaccines in
distinct animal models is considered. This background information and work
presented in Chapter 2 forms the basis for the model used for the core research
effort presented in Chapter 3.
In Chapter 3, a series of experiments in the Syrian Golden hamster
(Mesocricetus auratus) model system demonstrates pre- and post-exposure
protection using rVSV-based vaccines against the human pathogenic hantavirus,
Andes virus. Data demonstrate significant post-exposure protection against
hantavirus with these rVSV-based vaccines compared to previously reported
vaccine constructs.
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In the final chapter (Chapter 4), future directions for design and
development of replication-competent rVSV-based vaccines are discussed. The
approaches and lines of experimentation described extend beyond the scope of
this dissertation project and forward this work to a point where these rVSV-based
vaccines may be used in other animal model systems thereby testing the utility of
these constructs. Implementation of replication-competent vaccines (rVSV-based
or otherwise) as standard medical practice remains controversial. However, the
emergence of, and inability to predict and control devastating outbreaks of highly
pathogenic viruses may result in the future testing and use of this class of
vaccines in humans.
Cumulatively, the body of work presented in this thesis contributes to a
larger body of literature on novel approaches to vaccine development and the
focus area of developing replication-competent vaccines for emergency use. It
further demonstrates how vaccine platforms such as rVSV-based vectors can be
tailored to elicit specific responses while decreasing side effects often seen with
traditional vaccines.
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CHAPTER 1 INTRODUCTION
Hantaviruses and a Rhabdovirus Reverse Genetic System
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Hantaviruses: Introduction

Hantaviruses are a group of zoonotic pathogens that are part of the virus
family Bunyaviridae. Hantaviruses present as a single-stranded segmented RNA
genome of approximately 12.1 kb divided into three segments: a large segment
(L), a medium segment (M), and a small segment (S) of RNA lengths 6.5 kb, 3.63.7 kb, and, 1.6-2 kb, respectively (Schonrich et al. 2008). The hantavirus virion
presents as an enveloped pleomorphic pseudo-spherical particle with a diameter
ranging from 80-120 nm (Schonrich et al. 2008). Interestingly, each of the three
RNA segments comprising the virion are packaged in a separate nucleocapsid.
The three nucleocapsids are bound within the virus particle and surrounded by a
common cell-derived lipid bilayer featuring the viral glycoprotein spike complex
(Plyusnin et al. 1996; Vaheri et al. 2013).
The hantaviruses differ from the rest of the Bunyaviridae family in that they
are the only group that are transmitted by a rodent vector. It has been proposed
that hantavirus transmission can occur through the inhalation of dried rodent
excreta (Colleen et al. 2010). In contrast, the other genera of bunyaviruses are all
arthropod-borne (Plyusnin et al. 1996; Liu et al. 2012). Hantavirus genotypes are
commonly grouped together based on their biogeography. Those from Europe
and Asia are known as the “Old World” hantaviruses whereas those found in
North America and South America are known as ”New World” hantaviruses
(Figure 1-1). All hantaviruses are non-pathogenic in their natural hosts and
indeed many do not cause disease in humans. However, several hantaviruses of
both “Old World” and “New World” lineages can cause severe disease in
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humans. (Hantaviruses that cause disease in humans are classified as
Biosafety Level 3 pathogens because of the threat of severe disease without
the availability of therapeutic treatments or preventative vaccines).
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Figure 1-1: Hantavirus Global Distribution Map.
The map above depicts the global distribution of hantaviruses which is closely
mirrored with the ranges of their natural hosts. Used with permission of Dr. David
Safronetz 2016.
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Hantaviruses: History

Based on historical descriptions of symptoms for a variety of human
ailments, it has been suggested that hantaviruses have been responsible for
human disease for at least a century (Khaiboullina et al. 2005). However, the first
well-documented emergence of hantavirus-induced disease in humans occurred
during the Korean War where several thousand troops from the United Nations
contracted an acute febrile illness, which was initially designated “Korean
hemorrhagic fever” (Jonsson et. al 2010). This disease, now referred to as
hemorrhagic fever with renal syndrome (HFRS), is characterized by intense
headaches, fever, chills, and abdominal pain followed by later symptoms which
can include low blood pressure, kidney failure, vascular leakage and other
hemorrhagic manifestations (Linderholm et al. 2001). The causative agent was
later identified (ca. 1970s) as a virus from field mice (Apodemus agrarius) (Lee et
al.1978). The virus was named Hantaan Virus from the region where the host
rodent was captured - near the Hantaan River between North and South Korea,
close to the 38th parallel (Lee et al. 1982; Lindkvist et al. 2008).
Today, hantaviruses continue to be among some of the most concerning
etiological agents of emergent zoonotic infectious diseases and are considered a
significant threat worldwide. The viruses are maintained in reservoirs of natural
hosts. Geographic distribution of these natural hosts and epidemiology
associated with these viruses are congruent.
In the Old World, the majority of hantavirus cases have been reported in
Europe (e.g., Russia) and Eastern Asia. For example, hantavirus is widespread
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in China. Some reports estimate that hantavirus-induced disease in China
accounts for ~90% of the world’s recorded cases per year (Liu et al. 2012).
The Hubei province of central China has often recorded the highest annual
occurrence of HFRS in the world. Over the last 20 years, rapid urbanization in
China has undoubtedly contributed to the increasing rate of HFRS. Rapid
socioeconomic growth, modern transportation, and extensive migration from rural
to urban areas has contributed to an expanded geographic range for natural
hantavirus hosts. The concomitant increase in human population density in
Chinese cities has resulted in an increase in the frequency of cases in Northern
China (e.g., Beijing and Mongolia), a region where cases have historically been
rare to nonexistent (Liu et al. 2012).
In the New World, at least two highly virulent strains of hantavirus have
been well-characterized. Although hantavirus diseases occur less frequently in
the Americas, the lethality rates can reach as high as 40% with some of the more
pathogenic strains (Safronetz et al. 2009).
Since the isolation of the first New World hantavirus in 1993 (Nichol et al.
1993), cases of hantavirus-induced human disease have been reported in the
western region of the United States and several countries in Central and South
America. However, disease induced by New World hantaviruses differs
significantly from that caused by hantaviruses in Europe and Asia. Specifically,
New World hantavirus results in vascular leakage in the lungs, pulmonary
edema, and cardiovascular collapse. The disease is called Hantavirus
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Cardiopulmonary Syndrome (HCPS). Two species of the virus are responsible
for HCPS: Sin Nombre Virus (SNV) and Andes Virus (ANDV).
SNV was isolated in 1993 in the southwestern United States (i.e., New
Mexico). SNV is highly virulent, resulting in up to 35% lethality (Schonrich et al.
2008). ANDV was subsequently isolated in 1997 after an outbreak in Chile and
was later responsible for additional HCPS outbreaks in both Chile and Argentina
(Lopez et al. 1997). Of the 22 described hantaviruses, ANDV is considered one
of the “most deadly” hantaviruses (Schonrich et al. 2015). Outbreaks of ANDV
have been reported to cause case fatality rates exceeding 40%. It is also the only
hantavirus capable of transmission directly from human–to–human (MartinezValdebenito et al. 2014).
Hantavirus-induced diseases including HFRS and HCPS continue to
emerge (and re-emerge) worldwide with annual documented case totals in
Europe and Asia reaching up to 200,000 and case fatality rates as high as 10%
(Safronetz et al. 2011). Despite causing unique symptomology, both hantavirusinduced diseases cause vascular leakage and thrombocytopenia. North
American and South American strains of SNV and ANDV continue to be the most
devastating in terms of mortality (Clement et al 2014).

Response to Hantaviruses

The clinical manifestation of hantavirus infection in humans is acute
affecting renal, cardiac, pulmonary, central nervous system, and endocrine
function. Two separate hantavirus-induced diseases in humans have been
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defined and studied – HFRS caused by Old World hantavirus and HCPS
caused by New World hantavirus. HFRS is characterized by a high fever which
can be accompanied by headache, abdominal pains, backache and kidney
dysfunctions. HFRS disease is highly variable and is thought to depend heavily
on the hantavirus genotype and host genetic factors (Vaheri et al. 2013). HCPS
is also a severe disease which is often associated with respiratory failure from
pulmonary edema (Duchin et al. 1994). Despite causing separate diseases, Old
World and New World hantaviruses share common features at the cellular level
leading to detrimental impact on the host. These effects include an acute phase
characterized by the aforementioned symptoms but may also lead to long-term or
“chronic” debilitation. Specifically, hantaviruses infect and replicate primarily in
endothelial cells increasing capillary permeability. Altering capillary permeability
results in extravasation of fluid into alveolar spaces causing hypotension,
pulmonary edema, and thrombocytopenia (Vaheri et al. 2013). Interestingly, the
viral infection does not appear to cause notable cytopathic effects or cellular
necrosis. Instead, it is proposed that infection of endothelial layers modulates an
immuno-pathological response that is activated by infected endothelial cells and
migrating blood mononuclear cells (Khaiboullina et al. 2005). Frankly, the exact
mechanism by which immunopathology ensues after hantavirus infection is
poorly understood and continues to be a core focus of current research
(Schonrich et al. 2008).
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Natural Reservoirs of Hantaviruses

Hantaviruses have a unique coevolutionary history with their specific
host rodent species. This relationship between the virus and the natural host
species has resulted in persistence of the virus which causes no signs of disease
in the rodent population. It appears that the virus/host systems are highly coevolved and viral persistence, in the absence of disease, is mediated by both the
virus and the host to ensure the survival by both. (Easterbrook et al. 2008).
Laboratory-infected animals are not able to completely clear the virus, and it is
speculated that low levels of viral replication persist over the lifetime of the
animal accompanied with the persistent shedding of that virus in the host urine,
feces and saliva.
It appears that the hantavirus infection is spread through the rodent
population when exposed to contaminated dust from the excretia of other
infected rodents, as well as biting and scratching behavior between individuals.
The grooming habits of animals and their cagemates has also been observed
and thought to contribute as well (Hw et al. 1981). Maternal transmission to
offspring is not thought to be a major route of transmission due to passive
transfer of protective maternal antibodies though milk (Botten et al. 2002;
Dohmae et al. 1995).
Of the most common strains of hantavirus that occur in the old world the
natural reservoirs tend to be associated with 2 families of rodents Murinae and
Arvicolinae. The new world hantavirus typically has hosts in the rodent subfamily
Sigmodontinae (Schonrich et al. 2008; Khaiboullina et al. 2005). In that only a
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small percentage of rodents and insectovore species have been tested for
hantavirus infection, it is expected that many more species of hantavirus will be
discovered in the future (Plyusnin et al. 1996).

Biology and Life Cycle of Hantaviruses

The viral RNA segments are designated as the S, L, and M segments and
encode the nucleocapsid protein (NP), the viral RNA polymerase (RdRp), and
the glycoprotein precursor (GPC), respectively (Löber et al. 200).
Hantaviruses are thought to enter their host cells via a clathrin dependent
endocytosis mechanism (Jin et al. 2002) through the use of integrin receptors
(Wickham et al. 1994; Roivainen et al. 1994; Jackson et al. 1997; Guerrero et al.
2000). The human integrin alpha(v)beta(3) is one receptor that is expressed on
human endothelial cells and allows entry of HFRS and HCPs causing hantavirus
species (Gavrilovskaya et al. 2008). Interestingly, several species of nonpathogenic hantaviruses have been shown to use the alpha(v)beta(1) integrin
(Gavrilovskaya et al. 2002).
After the virus particle is internalized the RNA segments are released into
the cytoplasm accompanied by an RNA dependent RNA polymerase (RdRp)
which initiates primary transcription of viral proteins (Jin et al. 2002). Once the
production of viral components have accumulated to the proper levels, the
remaining morphogenesis, which is not completely understood, is completed as
the virus buds in the Golgi (Figure 1-2) (Plyusnin et al. 1996).
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The majority of hantavirus species that cause HFRS and HPS do not
cause cytopathic effects in most cell types. Therefore, virus-induced disease is
likely caused by indirect mechanisms including the host immune response and
disregulation of the chemokine and cytokine responses. Because the main
target cells are endothelial cells, it is thought that hantavirus disease and
pathogenesis is linked to the cellular response activated in endothelial cells.
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Figure 1-2: Hantavirus life cycle schematic.
Represents the major steps in the lifecycle of a hantavirus in the host cell.
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The viral glycoprotein is synthesized as a glycoprotein precursor
molecule by ribosomes bound to the endoplasmic reticulum (Pensiero et al.
1992; Schmaljohn et al. 1987; Khaiboullina et al. 2005). The precursor
molecule is then translocated to the ER via a signal peptide where it is cleaved
by the signal peptidase at a cut site with conserved amino acid sequence of
“WAASA” into the two glycoprotein subunits G1 and G2 (Löber et al. 2001).
Formation of the G1/G2 complex allows translocation to the Golgi where the final
maturation steps take place and become ready for viral assembly. The
cytoplasmic tails of the G1/G2 complex interact with the nuclear protein/viral RNA
complex and initiate viral budding from the Golgi. The newly-formed viral
particles are then transported to the plasma membrane where viral egress takes
place (Vaheri et al. 2013).
Some of the major hurdles in studying hantavirus infection and its influence
on the host immune response is the limited availability of animal models. The only
adult small animal disease model currently available is the ANDV infection of the
Syrian golden hamster (Safronetz et al. 2012). While the use of a STAT1 knock out
mouse model was explored in chapter 2 it was not intended for use as a lethal ANDV
challenge model. An immunocompromised mouse model would be valuable as a
model for rVSV vector efficacy in stimulating the immune system when paired with
commonly available reagents for exploring the in vivo immune response in murine
models. Thus, chapter 2 explores the use of the STAT1 knock out mouse model
and forms the basis for the decision to use the hamster model in the research
presented in Chapter 3. In addition, two nonhuman primate disease models have
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been described, one for Sin nombre virus (Safronetz et al. 2014) and the other one
for Puumala virus (Groen et al. 1995), but neither are well established at this time.
This leaves the ANDV hamster disease model as the currently best choice for
hantavirus vaccine efficacy testing.
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Vesicular Stomatitis Virus (VSV) Background

VSV as a Vaccine Platform
As our knowledge of the immune response and vaccines increase, the
scientific and medical fields will have a greater ability to design tools against
human disease. Vaccines that are specifically designed to mediate an effective
immune response and elicit a custom tailored response to a specific disease can
be more efficient and have reduced side effects. Viruses that are designed to
stimulate specific immune responses are getting more attractive and rVSV has
been proven to be a very promising platform to develop viral therapeutics.
Because VSV is an RNA virus it is thought that problems associated with
DNA virus based platforms could be circumvented with the RNA based rVSV
platform by avoiding viral replication in a cell's nucleus. DNA virus-based
therapeutics have come under scrutiny because of the possibility of the virus to
cause mutations to the host cell’s DNA in addition to the disruption of host cell
transcription processes.
Because of the wide distribution of phosphatidylserine (the host
membrane component which VSV glycoprotein (G) binds to in order to facilitate
entry) in host cells across the domains of life the VSV has an exceptionally broad
tissue tropism. Replacement of the native VSV-G with other viral glycoproteins
allows the engineering of recombinant vectors (rVSV) that have more specific
host tissue/cellular targeting and thus likely less side effects.
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Since the reverse genetics system allows precise tailoring of the virus, it
can be attenuated by careful manipulation of the genome and the deletion of
viral pathogenicity factors to reduce side effects while still being replication
competent. The rVSV vaccine vectors have many other advantages, such as the
ability to be administered as a single dose and given through other routes such
as mucosal membranes that do not involve injection but are still able to elicit a
robust protective immune response (Schlereth et al. 2000; Roberts et al. 1998).
The ability to manipulate and grow the virus in the lab is straightforward
and the virus is easily grown rapidly and to high titers in tissue culture. It grows
so well that it has been suggested in the rVSV-HIV literature that one liter culture
of supernatant volume could generate enough vaccine material to vaccinate over
1 billion people (Rose et al. 2001). Because of these advantages, this study
focuses on using a rVSV based vector as a vaccine against lethal Andes virus
Infection.
VSV Introduction

VSV is a non-segmented negative stranded RNA virus in the family of
Rhabdoviridae. Approximately 170 members of the Rhabdoviridae have been
discovered and these members have an extremely wide host range which allow
infection across two kingdoms of life (Ghanem et al. 2012).
VSV has a small and simple genome structure which is approximately 11
kb pairs and is composed of five genes. The genes are arranged in the 3' to 5'
direction and are arranged in the conserved order N-P-M-G-L. The first gene (N)
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encodes the nucleoprotein which is responsible for forming the nucleocapsid
around the viral RNA. The P gene encodes the phosphoprotein, which, in
combination with N, is used for RNA synthesis. The matrix protein (M gene)
provides the structural system between the nucleocapsid and the viral envelope.
The G gene encodes the glycoprotein which allows attachment to target cells and
initiates fusion of the virus particle the host cell membrane. The L gene encodes
for the viral RNA polymerase which acts as both a viral transcriptase to produce
viral mRNAs and a replicase which is responsible for producing successive
copies of the genome. The three prime end of the N gene contains a
transcriptional start sequence which initiates transcription until the polymerase
encounters a series of U residues at the end of the gene. These residues cause
the polymerase to stutter back-and-forth producing a poly-A tail before the mRNA
is discharged. The nearby downstream restart signal causes the polymerase to
re-engage and continue transcription of the next downstream gene. Production of
a decreasing gradient of mRNAs is produced from the viral genome, where those
near the 3' end of the genome are produced in much higher quantities. Because
the polymerase always starts at the 3’ end of the genome and has a chance to
dissociate at the end of each gene after transcription, and genes that are closer
to the 5' end of the genome are produced much less abundantly (Figure 1-3).
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Figure 1-3: VSV Transcription.
Represents the sequential transcription of viral genes in the VSV genome.
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The order of these genes is highly conserved in this group of viruses and
is a simple and efficient way to regulate viral gene expression levels. After viral
N and P proteins have accumulated to high enough levels in the host cell, the
polymerase is able to synthesize full-length, positive strand, anti-genome RNAs.
The anti-genome, in turn, serves as a template for synthesis of full-length
genomes which are incorporated into new virus particles and then bud out of the
host cell to complete the viral replication cycle.

VSV Infection & Disease in Animals and Humans

Rhabdoviridae hosts include insects, fish, plants, and vertebrates. VSV
can cause vesicular lesions in domestic animals (cattle, sheep, horses, pigs)
which self-resolve, and, after healing, leave the animals with no long term ill
effects. The early clinical symptoms of VSV infection closely mimic the symptoms
of hoof-and-mouth disease and the mis-diagnosis has the potential to cause
economic loss.
Information supporting VSV’s role in human disease is rare. Although VSV
has been shown to be able to infect humans, it is generally believed to be largely
asymptomatic with the viral infection self-resolving (Lichty et al. 2004). VSV is
endemic in regions ranging from the southern portion of Mexico to the northern
part of South America, and also occurs as a livestock animal pathogen in several
states in the US (Flanagan et al. 2001). Although human seroprevalence against
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VSV is reported in these endemic regions, the clinical disease (described as a
flu-like illness) rates attributed to VSV are low (Roberts et al. 1999).

rVSV Reverse Genetics System

Members of the Rhabdoviridae family have proven to be important
biomedical tools. Particularly, in the case of VSV, they can easily be genetically
engineered to become useful research tools such as vectors, vaccines, viral
tracers in neurotropism studies, and basic viral lifecycle studies. One of the
primary features that makes VSV so useful is its ability to be manipulated using a
reverse genetics system.
Although there are several systems established for rescuing members of
the Rhabdoviridae family, I used a rescue plasmid encoded T7 RNA polymerase
system which uses 6 “helper” plasmid containing the genes for N, P, M, G, L and
the T7 polymerase.
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Figure 1-4: VSV Reverse Genetics System.
The bivalent vaccine vector rVSVΔG-ZEBOVgp-ANDVgpc was rescued using the
VSV reverse genetics system by amplifying and cloning the ZEBOVgp and
ANDVgpc open reading frames into the pATX plasmid downstream of the M
gene.
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Detailed description of the rVSV rescue system have been described at
length in previous literature (Figure 1-4) (Garbutt et al. 2004; Tsuda et al. 2011;
Brown et al. 2011). Briefly, a mixed culture of Vero cells and 293T cells were
grown to a confluence of 90%. The cell co-culture was then transfected with the
rVSV rescue plasmid in addition to the 6 helper plasmids listed above. The
transfected co-cultures were then maintained for 12-14 days after transfection
until cytopathic effects (CPE) were observed indicating successful viral rescue
and replication.
In this study we explored the ability of using a combination of
glycoproteins from the vastly different virus strains, Andes virus and Ebola virus,
to design a more potent and effective vaccine platform that may have broad
applications for future vaccine development.
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Objectives and Hypothesis

A previous vaccine efficacy study (Brown et al. 2011) focusing on the
protection of an rVSV vector expressing the ANDV glycoprotein precursor
(rVSV∆G-ANDVgpc) against lethal ANDV infection used an unrelated rVSV
vector expressing the ZEBOV glycoprotein (rVSV∆G-ZEBOVgp) as a negative
control which was expected to not provide any protection in the lethal ANDV
infection study. Interestingly, rVSV∆G-ZEBOVgp provided varying degrees of
protection in hamsters against ANDV infection when administered between 7
days prior and 3 days after ANDV challenge. This data indicates that rVSV vector
vaccination can result in unspecific protective efficacy against heterologous
challenge.
We hypothesize that the ZEBOVgp will target important immune cells like
monocytes, macrophages and dendritic cells, which can lead to a rapid and
enhanced immune response that is broadly protective against heterogeneous
viral challenge. This response will be a valuable trait for vectors used in periexposure prophylaxis where a rapid, but short lived protective response may
suppress viral replication and give the adaptive immune response (if an
appropriate immunogen is provided) a better chance to kick in and offer a longer
term immunity.
In this study, bivalent vaccine vectors (rVSV∆G-ZEBOVgp-ANDVgpc;
rVSV∆G-ANDVgpc-ZEBOVgp) including the ZEBOVgp will be utilized based on
the idea that ZEBOVgp may target the vaccine vectors to important immune
cells, such as monocytes, macrophages and dendritic cells, strongly enhancing
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innate and adaptive immune responses and, thus improve protective efficacy
against a lethal heterologous ANDV challenge. The study further looks at the
effects of the insertion and position of the foreign viral glycoproteins (here
ZEBOV and ANDV) into the genome of rVSV and how it influences the rVSV
when used as a vaccine utilizing the ANDV hamster challenge model.
To generate the vaccine vector an Indiana strain of VSV is modified by
removing the native glycoprotein and replacing it with two other viral proteins,
ZEBOV gp and ANDV gpc. Two monovalent (rVSVΔG-ANDVgpc and rVSVΔGZEBOVgp) and two bivalent [rVSVΔG-ANDVgpc-ZEBOVgp (Tsuda et al. 2011)
and rVSVΔG-ZEBOVgp-ANDVgpc] vectors are compared in this study and the
results are described in chapter 3.
While the hamster model is sufficient for testing the protective effects of
vaccines and survival, the shortcomings become very evident when wanting to
explore the specific mechanisms involved in the resulting changes in survival.
There is a lack of commercial reagents specific to the hamster which makes it
very difficult to study the immune response mechanism involved in protection. It
would therefore be desirable to have a mouse model available because of the
available reagents to study response mechanisms in mice. Since it has been
shown before that immunosuppression of hamsters can result in a lethal model
for SNV (Brocato et al. 2014) it would be ideal to demonstrate a lethal model of
ANDV in immunocompromised mice to facilitate the study of the mechanism of
immune response in mice since there are many more commercial reagents
available to study immune mechanisms in the murine models. Unfortunately,
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such a murine model does not yet exist. However, as a first step towards
developing such a model we investigated the possibility of testing selected
rVSV-based vaccine candidates in such immunocompromised mouse models
and the results of this work are discussed in chapter 2.
Because hantaviruses are continually emerging as zoonotic pathogens the
threat of significant disease in humans have increased the interest in studying
hantavirus not only to research viral pathogenesis but also to evaluate possible
medical interventions such as vaccines or other therapeutics. In particular, a fast
acting vaccine would be particularly important for the Andes virus as it has been
shown to successfully be transmitted from human-to-human.
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CHAPTER 2 STAT1-DEFICIENT MICE ARE NOT AN APPROPRIATE
MODEL FOR EFFICACY TESTING OF RECOMBINANT VESICULAR
STOMATITIS VIRUS-BASED FILOVIRUS VACCINES
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Abstract

STAT1-defiecient mice lack a response to interferon α, β and γ and
therefore allowing for replication of non-adapted wild-type (wt) Ebola- and
Marburgviruses. We sought to establish a mouse model for efficacy testing of
live-attenuated recombinant vesicular stomatitis virus (rVSV)-based filovirus
vaccine vectors using wt Ebola- and Marburgvirus challenge strains. While
infection of immunocompetent mice with different rVSV-based filovirus vectors
did not cause disease, infection of STAT1-deficient mice with the same vectors
resulted in systemic infection and lethal outcome for the majority of tested rVSVs.
Despite differences in viral loads, organ tropism was remarkably similar between
rVSV filovirus vaccine vectors and VSVwt with the exception of the brain. In
conclusion, STAT1-deficient mice are not an appropriate immunocompromised
mouse model for efficacy testing of live-attenuated, replication-competent rVSV
vaccine vectors.
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Introduction

Members of the family Filoviridae, Ebola- and Marburgviruses, are pathogens
causing viral hemorrhagic fever in nonhuman primates and humans (Feldmann
et al. 2013). While outbreaks of filovirus hemorrhagic fever have occurred mainly
in their endemic area in Central Africa, currently, the biggest documented Ebola
virus (EBOV) outbreak is still ongoing in West African countries such as Guinea,
Liberia and Sierra Leone. Not only has the virus spread from there into
neighboring Mali, it was also introduced to Senegal, Nigeria, Spain, the United
Kingdom and the United States where further spread of the virus was
successfully stopped (WHO 2015). Despite tremendous effort being made to
accelerate Phase 1 Clinical trials for experimental vaccines and therapeutics
(www.ClinicalTrials.gov), there is still no approved countermeasure available.
One of the experimental vaccine platforms currently in Phase 1 Clinical trials is
based on recombinant vesicular stomatitis virus (rVSV). The rVSV vaccines for
EBOV, strain Mayinga (EBOV-May) and Marburg virus (MARV), strain Musoke
(MARV-Mus) are attenuated and have been shown to protect rodents and
nonhuman primates from lethal disease (Jones et al. 2005) and subsequently
vaccine vectors for other MARV isolates and ebolavirus species have been
developed (Marzi et al. 2011).
Protective efficacy testing of vaccine candidates against challenge with
filoviruses isolated directly from human or wildlife (wild-type (wt) isolates) can
only be performed in macaques or immunocompromised rodents (i.e. STAT1-/or interferon α/β receptor (IFNAR)-/- mice), where infection causes disease
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without previous adaptation (Bray et al. 2001; Raymond et al. 2011). While
STAT1-/- mice have been shown to develop lethal disease after infection with
the majority of wt filovirus isolates (Raymond et al. 2011), IFNAR-/- mice seem
more resistant to infection with wt filoviruses i.e. Reston virus (RESTV) (Bray
2001). As the rVSV vector for EBOV-May did not cause disease in
immunocompromised NOD-SCID mice (Jones et al. 2007), we sought to
evaluate the usefulness of STAT1-/- mice as a model for the initial evaluation of
the protective efficacy of new or improved rVSV filovirus vaccine vectors.
We hypothesized that the attenuated rVSV vectors would also be attenuated in
this immunocompromised mouse model, in which rVSVwt causes lethal disease
(Katzenell et al. 2014). We found, however, that vaccination of STAT1-/- mice
with 4 different monovalent rVSV vectors individually expressing different filovirus
glycoproteins (GP) resulted in systemic infection with lethal outcome for most of
the rVSV vectors. In conclusion, while STAT1-/- mice are an animal model for wt
Ebola- and Marburgvirus infections, this animal model can likely not be utilized
for efficacy testing of live-attenuated vaccines such as the rVSV-based vectors.
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Methods
Animal ethics and safety statements.

Research was approved and conducted in compliance with the guidelines of the
NIAID/RML Institutional Animal Care and Use Committee (IACUC). The facility
where this research was conducted is fully accredited by the Association for the
Assessment and Accreditation of Laboratory Animal Care International
(AAALAC) and has an approved Office of Laboratory Animal Welfare (OLAW)
Assurance (#A4149-01). All procedures were conducted by trained personnel
under the supervision of veterinarians, and all invasive clinical procedures were
performed while animals were anesthetized. Early endpoint criteria, as specified
by the IACUC approved scoring parameters, were used to determine when
animals should be humanely euthanized. rVSV vectors are classified as biosafety
level 2 (BSL2) pathogens and all work with the live vectors was approved by the
Institutional Biosafety Committee (IBC) under BSL2 conditions.
Virus recovery, propagation and purification:

The following rVSVs were recovered from full-length plasmids and propagated as
described previously (Lawson et al. 1995; Garbutt et al. 2004; Marzi et al. 2011):
rVSVwt, rVSV/EBOV-May-GP, rVSV/RESTV-Pen-GP (RESTV, strain
Pennsylvania), rVSV/MARV-Mus-GP, and rVSV/MARV-Ang-GP (MARV, strain
Angola). Viruses were subsequently purified through a 20% sucrose cushion,
resuspended in DMEM (Sigma, St. Louis, MO) containing 10% FBS (Life
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Technologies, Carlsbad, CA), aliquotted and stored at -80ºC. Viral titers were
determined performing classical plaque assay on Vero cells (Marzi et al. 2011)
and the median tissue culture infectious dose (TCID50) using the ReedMuench method (Reed et al. 1938).
Growth kinetics.

Vero E6 cells were seeded in a 24-well plate the day before the experiment.
Infection was performed with rVSVwt, rVSV/EBOV-May-GP, rVSV/RESTV-PenGP, rVSV/MARV-Mus-GP and rVSV/MARV-Ang-GP at a multiplicity of infection
of 0.001 for one hour. Following washes with plain DMEM, cells in each well
were covered with 1 ml DMEM/2% FBS. At time points 0, 6, 12, 24, 36, 48, 72,
and 96 hours post infection 30 μl supernatant were collected. Samples were
stored at -80ºC before titration on Vero E6 cells.
Mouse experiments.

Four to six week old 129S6/SvEv control and 129S6/SvEv-STAT1-/- mice
(Harlan Laboratories) were inoculated with the indicated dose of rVSV (diluted in
sterile DMEM) by intraperitoneal (i.p.) injection in a total volume of 200 μl. The
animals were monitored for signs of illness and weighed daily. On necropsy
days, mice were anesthetized, bled, euthanized and tissue samples were taken
and stored at -80ºC. Surviving mice were euthanized 21 days after infection, and
serum was collected for antibody titrations.
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Titrations.

Vero E6 cells were seeded the day before titration in 96-well plates. Tissue
samples were homogenized in DMEM, cleared from debris by centrifugation and
serial dilutions were prepared. Blood and cell culture supernatants were thawed
and serial dilutions were prepared. A confluent layer of Vero E6 cells was
infected in triplicates per dilution for one hour at 37ºC, then 100 μl DMEM/2%
FBS were added. After 2-6 days the plates were analyzed for VSV specific
cytopathic effect (CPE) and the median tissue culture infectious doses (TCID50)
were calculated using the Reed-Muench method (Reed et al. 1938).
Results & Discussion

For the development of filovirus vaccines, promising candidates will require
efficacy testing, which involves challenging immunized animals with infectious wt
Ebola- and Marburgviruses. In the case of small rodent models, only the use of
immunocompromised mouse strains or rodent-adapted viruses that cause severe
disease are suitable for adequately evaluating vaccine efficacy. We sought to
establish a mouse screening model for efficacy testing of live, attenuated
vaccines, in which wt stocks of Ebola or Marburg virions could be used to
challenge immunized animals. We chose STAT1-/- mice, which lack a response
to interferon α, β and γ, and have previously been shown to be largely
susceptible to wt filovirus infections (Raymond et al. 2011). The potential
feasibility of this approach was supported by the self-limiting replication of the
first rVSV filovirus vector, rVSV/EBOV-May-GP, in immunocompromised NOD-
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SCID mice resulting in an asymptomatic phenotype (Jones et al. 2007). In
contrast, VSVwt infection is known to cause lethal disease in STAT1-/- mice
(Katzenell et al. 2014), but replication of rVSV vectors expressing filovirus GPs
instead of the VSV glycoprotein is known to be attenuated in vitro and in vivo
(Garbutt et al. 2004; Jones et al. 2005).
In a first experiment we compared the growth kinetics of rVSVwt, rVSV/EBOVMay-GP, rVSV/RESTV-Pen-GP, rVSV/MARV-Ang-GP and rVSV/MARV-Mus-GP
in Vero E6 cells over 72 hours. As expected, 3 of the 4 different rVSV vectors
replicated similarly in cell culture and were strongly attenuated (several log10)
compared to rVSVwt, but reached the same end titer at 72 hours. The exception
was rVSV/MARV-Ang-GP, which was less attenuated over the same time period
(Fig. 2-1A). This finding is surprising and further investigations need to address
potential unique features of the MARV-Ang-GP that may influence infectivity, as
the glycoprotein mediates virus entry and is the only difference among all
vectors.
We next moved on to perform in vivo characterization of the rVSV vectors. First,
groups of 3 129S6/SvEv control mice (immunocompetent) were i.p. infected
(usual route of rVSV vaccination in mice) with 10^7 pfu of the 4 rVSV filovirus
vectors and rVSVwt; none of the animals developed weight loss or other signs of
disease (data not shown). Second, groups of 3 STAT1-/- mice were i.p. infected
with different doses (ranging from 10^4-10^7 pfu/animal) of the rVSV vectors and
monitored daily for weight change and disease progression. As expected,
rVSVwt caused lethal outcome in STAT1-/- mice at all doses tested (Fig. 2-1B).
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Surprisingly, the only clearly attenuated vector was rVSV/MARV-Mus-GP, for
which infection resulted in 67-100% survival (Fig. 2-1C right panel). While most
of the mice survived, all infected animals displayed signs of disease including
weight loss (data not shown). Interestingly, rVSV/EBOV-May-GP was only
slightly attenuated at the two lower doses with all animals succumbing to
infection in a dose-dependent manner (Fig. 2-1D left panel). Similarly,
rVSV/RESTV-Pen-GP was only minimally attenuated in the groups receiving the
two lower doses with increased time to euthanasia (Fig. 2-1D right panel).
Interestingly, rVSV/MARV-Ang-GP was advanced in disease progression with all
animals succumbing to infection slightly faster than rVSVwt infected mice
independent of the dose (Fig. 2-1C left panel).
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Figure 2-1: Wild-type recombinant vesicular stomatitis virus (rVSVwt) and
rVSV filovirus vaccines replicate comparably in vitro and can cause lethal
infection in Stat1−/− mice.
A, In vitro growth kinetics on Vero E6 cells. Infection with a multiplicity of infection
of 0.001 resulted in the depicted growth curves for rVSVwt (black circle on a
black solid line), rVSV/EBOV-May-GP (Ebola virus strain Mayinga; black square
on a black dotted line), rVSV/RESTV-Pen-GP (Reston virus strain Pennsylvania;
grey circle on a grey solid line), rVSV/MARV-Ang-GP (Marburg virus strain
Angola; black solid diamond on a black dotted line), and rVSV/MARV-Mus-GP
(Marburg virus strain Musoke; black diamond on a black solid line). B–D, Groups
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of 3 mice were infected with the indicated vector and monitored daily for weight
loss and signs of illness. Survival curves are shown. Abbreviations: PFU,
plaque-forming units; TCID50, 50% tissue culture infectious dose.
All surviving immunocompetent control and STAT-1 knockout mice were
euthanized on day 21 after infection and serum was collected for the analysis of
humoral immune responses. Every animal seroconverted to VSV with titers
≥102,400 confirming that all mice were indeed infected with rVSV (data not
shown). In addition, we compared GP-specific IgG responses in rVSV/MARVMus-GP infections of immunocompetent control and STAT1-/- mice, which
developed IgG titers up to 25,600 and 6,400, respectively (data not shown). The
lower titers detected in STAT1-/- mice are not unexpected, as these animals are
defective in cell signaling pathways that contribute to T- and B-cell responses. In
macaques, however, a MARV-Mus-GP-specific IgG titer of 640 has been
sufficient for protection against lethal MARV-Mus challenge (Jones et al. 2005;
Mire et al. 2014), suggesting that the rVSV-immunized STAT1-/- mice might be
protected from lethal filovirus challenge.
While it became obvious that STAT1-/- mice are not an appropriate model
for testing protective efficacy of rVSV filovirus vectors, we sought to characterize
the disease caused by all the rVSV vectors in these mice. In order to determine
the tissue tropism and organ virus load, we infected groups of 10 STAT1-/- mice
with 10^7 pfu of the different rVSV vectors and euthanized 5 animals each at 12
and 24 hours post inoculation. At the time of euthanasia, blood, lymph node,
lung, heart, liver, spleen, kidney, and brain samples were collected and frozen for
virus titration. As expected, the highest virus loads in all tissues were obtained for
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rVSVwt infected animals with titers comparable to previously published data
from VSV infected STAT1-/- or IFNAR-/- mice (Katzenell et al. 2014; Honke et
al. 2012). Notably, the lowest amounts of rVSVwt were consistently found in the
brain of all mice (Fig. 2-2A). Viremia and tissue titers were comparable for
rVSVwt and rVSV/MARV-Ang-GP infected mice at both time points (Fig. 2-2A, B
left panel), confirming systemic infection and similar disease progression (Fig. 21B, C right panel). The only notable difference was found for brain tissue, in
which rVSV/MARV-Ang-GP could only be detected in 1/5 mice at each time point
(Fig. 2-2B left panel).
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Figure 2-2: Recombinant vesicular stomatitis virus (rVSV) vectors replicate
systemically in Stat1−/− mice.
Groups of 5 mice were infected with 10^7 plaque- forming units of the respective
rVSV vector and euthanized at the indicated time points. Tissue samples were
collected, and virus titers were determined. The organ loads of rVSVwt (wild-type
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rVSV; A), rVSV/MARV-Ang-GP (Marburg virus strain Angola; B, left panel),
rVSV/MARV-Mus-GP (Marburg virus strain Musoke; B, right panel),
rVSV/EBOV-May-GP (Ebola virus strain Mayinga; C, left panel), and
rVSV/RESTV-Pen-GP (Reston virus strain Pennsylvania; C, right panel) per
group are shown. Error bars represent standard errors of the mean.
Abbreviation: TCID50, 50% tissue culture infectious dose.
Slightly lower virus titers were detected in blood and tissues of rVSV/EBOV-MayGP infected mice (Fig. 2-2C left panel), mirroring the slightly slower disease
progression compared to rVSVwt and rVSV/MARV-Ang-GP infected animals
(Fig. 2-1B, C left panel, D left panel). As noted with rVSV/MARV-Ang-GP infected
animals, rVSV/EBOV-May-GP was only found to replicate in the brain of 1 mouse
(Fig. 2C left panel). Infection of STAT1-/- mice with rVSV/RESTV-Pen-GP resulted
in viremia similar to animals infected with rVSV/EBOV-May-GP, but virus tissue
loads were lower and only detectable in liver, spleen and lymph node (Fig. 2-2C
right panel). This finding is in contrast to the lethal phenotype in STAT1-/- mice
(Fig. 2-1C right panel) and warrants further investigation. rVSV/MARV-Mus-GP
infection resulted in the lowest viremia and in reduced viral tissue loads of all
rVSV vectors (Fig. 2-2B right panel), which is in line with the attenuation of this
vector (Fig. 1D right panel), but it still caused systemic infection without reaching
the brain.
Notably, rVSV infected immunocompetent control mice did not show any
signs of disease and virus was only occasionally isolated from lymph nodes, liver
or spleen samples of mice infected with any of the rVSV vectors including
rVSVwt. Overall, infection of immunocompetent control mice did not result in
productive rVSV replication, but was sufficient to generate humoral immune
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responses (discussed above). For rVSV/EBOV-May-GP these antibody
responses have previously been shown to protect mice from lethal mouseadapted EBOV challenge (Jones et al. 2007).
While immunocompetent mice do not develop disease after infection with
wt Ebola- and Marburgviruses, it has been shown that STAT1-/- mice are
susceptible to infection with these pathogens leading to uniform lethality (Bray
2001; Raymond et al. 2011). Although kinetics of disease progression differed
among wt filoviruses, replication was similar for all with key target organs being
lymph nodes, liver and spleen (Raymond et al. 2011). Overall, organ tropism of
the rVSV filovirus vaccine vectors studied here in STAT1-/- mice was similar and
confirms a key role of GP in determining cell and tissue tropism (Feldmann et al.
2013). Interestingly, also the organ tropism of rVSVwt was similar (Katzenell et
al. 2014; Honke et al. 2012), which may be explained by the in general systemic
nature of infections in STAT1-/- mice caused by wt filoviruses, rVSV filovirus
vaccine vectors and VSVwt. The only exception was the brain, which seems to
be only a major target organ of VSVwt infection.
While STAT1-/- mice are not an appropriate animal model for evaluating
the protective efficacy of live-attenuated vectors such as the rVSV filovirus
vaccines, this animal model might be useful for further studies characterizing the
function of filovirus GPs. The remarkably different phenotypes displayed by the
two rVSV/marburgvirus-GP and the two rVSV/ebolavirus-GP vectors in STAT1-/mice are likely caused by different properties of their GPs, warranting further
investigations.
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CHAPTER 3 EVALUATION OF POST-EXPOSURE PROTECTION
CONFERRED BY VESICULAR STOMATITIS VIRUS-BASED VACCINES.
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Introduction

Hantaviruses are a group of zoonotic pathogens comprising the genus
Hantavirus within the Bunyaviridae family. They are enveloped particles
containing a tri-segmented, single stranded, negative sense RNA genome. The
three viral RNA segments are designated small (S), medium (M) and large (L)
and encode the nucleocapsid protein (NP), the glycoprotein precursor (GPC) and
the viral RNA polymerase (RdRp), respectively (Löber et al. 2001). Hantavirus
are rodent or insectivore-borne pathogens and primary transmission to humans
is thought to largely occur by inhalation of dried excreta (Jonsson et al. 2010).
Hantavirus infections in humans are associated with two clinical syndromes;
hemorrhagic fever with renal syndrome (HFRS) and hantavirus
(cardio)pulmonary syndrome (HCPS or here HPS), which are caused by Old
World and New World hantaviruses, respectively (Clement et al. 2014). Of the
22 described human-pathogenic hantaviruses, Andes virus (ANDV) is one of the
most virulent New World hantaviruses (Schonrich et al. 2015). ANDV has a HPS
case fatality rate of >40% and is the only reported hantavirus that is known to
transmit directly from human–to–human (Martinez-Valdebenito et al. 2014).
Therefore, among all New World hantaviruses a vaccine would be of particular
interest for ANDV, for which a hamster disease model has been established
(Hooper et al. 2001).
In a previous study we have demonstrated the potency of a live-attenuated,
recombinant vesicular stomatitis virus (rVSV)-based vaccine vector expressing
the ANDV glycoprotein precursor in place of the VSV glycoprotein (rVSVΔG-

50

Marceau, Joshua O., Ph.D., Fall 2016

Department of Biomedical Sciences

ANDVgpc) with complete and partial (90%) protection in the Syrian Golden
hamsters against lethal ANDV challenge when administered as close as 3 days
prior to and 24 hours post infection, respectively (Brown et al. 2011).
Surprisingly, a similar rVSV vaccine vector expressing the Ebola virus
glycoprotein (rVSVΔG-ZEBOVgp), used as a negative control, also mediated
partial protection against lethal ANDV challenge when administered between 7
days prior to 3 days post infection (Brown et al. 2011). Detection of strong
induction of innate immune responses, particularly through rVSVΔG-ZEBOVgp
(Brown et al. 2011), lead to the hypothesis that a bivalent vector expressing
ANDV GPC on the backbone of rVSVΔG-ZEBOVgp) would be a more potent
ANDV vaccine.
In this study we investigated the protective efficacy of two monovalent
(rVSVΔG-ANDVgpc and rVSVΔG-ZEBOVgp) and two bivalent rVSV vaccine
vectors (rVSVΔG-ANDVgpc-ZEBOVgp (Tsuda et al. 2011) and rVSVΔGZEBOVgp-ANDVgpc (this study)) in hamsters against lethal ANDV challenge. In
addition, two routes of immunization, intraperitoneal and intranasal, were
compared. The two bivalent vectors both mediated full protection when
administered even 3 days prior to ANDV challenge independent of the route of
immunization. The monovalent rVSVΔG-ANDVgpc was similarly protective but
intranasal immunization showed reduced efficacy when administered close to
challenge. The bivalent rVSVΔG-ZEBOVgp-ANDVgpc was most potent in postexposure treatment, followed by the monovalent rVSVΔG-ZEBOVgp. The
monovalent rVSVΔG-ANDVgpc was least potent in post-exposure treatment.
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Intraperitoneal immunization was superior over the intranasal route in postexposure treatment. Our data indicates the benefit of bivalent rVSV vaccine
vectors based on the rVSVΔG-ZEBOVgp backbone with the second
immunogen expressed in the downstream position in peri-exposure application.

Materials and Methods

Cells and Viruses:

Vero E6 (African green monkey kidney) and HEK 293T (human embryonic
kidney) cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM)
supplemented with 10% FBS, 1% L-Glutamine, penicillin/streptomycin. BHK-21
cells were maintained in Gibco Minimum Essential Media (MEM) supplemented
with 10% FBS, 1% L-Glutamine, penicillin/streptomycin . ANDV, strain Chile
9717869 (Meissner et al. 2001) (kindly provided by C. Schmaljohn, U.S. Army
Medical Research Institute of Infectious Diseases, Fort Detrick, MD), was grown
and titrated in Vero E6 cells as previously described (Safronetz et al. 2009).

Generation of rVSV Vectors:

The generation, growth and titration of rVSVs expressing the Ebola virus
glycoprotein (rVSVΔG-ZEBOVgp), the ANDV glycoprotein precursor (rVSVΔGANDVgpc) or both (rVSVΔG-ANDVgpc-ZEBOVgp) has been described
elsewhere (Garbutt et al. 2004, Brown et al. 2011; Tsuda et al. 2011). For the
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generation of rVSVΔG-ZEBOVgp-ANDVgpc), the open reading frame of the
ANDV glycoprotein gene was amplified by iProof High-Fidelity DNA
Polymerase (Bio-Rad) from plasmid DNA using the primers 5'GTAGTCGACCACCATGGAAGGGTGGTATCTGGTTGCTCTTGG-3’
(Sal1restriction site underlined) and 5'TACGCTAGCTACCTATTAGACAGTTTTCTTGTGTCCTCTCCTGGG-3' (Nhe1
restriction site underlined). The PCR product was digested with Xhol & Nhel,
purified using a PCR purification kit (Qiagen) and cloned into the pATX-VSVΔGZEBOVgp plasmid downstream of the ZEBOVgp ORF (Garbutt et al. 2004). The
resulting plasmid, pATX-VSVΔG-ZEBOVgp-ANDVgpc, was sequence-confirmed
prior to use. rVSVΔG-ZEBOVgp-ANDVgpc was rescued as described previously
(Garbutt et al. 2004). Briefly, Vero E6 and 293T cells were seeded together into
six-well plates at 1:6 and 1:4 dilutions, respectively. When the co-cultures
reached 90% confluence, cells were transfected with pATX-VSVΔG-ZEBOVgpANDVgpc (2µg) along with the VSV helper plasmids [SV-T7 (2.5µg), VSV-N
(0.5µg), VSV-L (0.25µg plasmid DNA), VSV-P (1.25µg), and pCAGGS-VSVG
(2µg)] using Lipofectamine 2000 transfection reagent (Invitrogen) and incubated
for 24 hours at 37⁰C (5% CO2). DMEM supplemented with 3% FBS, L-Glutamine,
penicillin/streptomycin (1ml/well) was added 24 hours after transfection. Every 12
hours, 20% of the medium was replaced to maintain the co-culture until
cytopathic effects (CPE) was observed 12-14 days post-transfection.
Supernatant (500µl) of CPE-positive cells was removed and placed onto fresh
Vero cells for an additional passage of the rescued rVSV. Supernatant was
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collected from both, the transfected co-culture and blind passage on fresh Vero
cells, to verify virus rescue by immunoblot (rVSV proteins) and RT-PCR (rVSV
genome) as described previously (Brown et al. 2011; Tsuda et al. 2011).
In vitro growth studies (Tissue Culture Infectious Dose 50 (TCID50) assay):

Vero cells were grown to 90% confluence and triplicates were inoculated
with rVSVs at an MOI of 0.1 and 0.001 for 1 hour at 37°C. Subsequently, the
inoculum was replaced with fresh DMEM supplemented with 3% fetal bovine
serum. At predetermined time points 250µl supernatant was collected from each
of the triplicate wells and frozen at -80°C. For titration, samples were serially
diluted ten-fold and the dilutions were used to inoculate 90% confluent Vero cells
(triplicates) for 1 hour at 37°C. Subsequently, the inoculum was removed and
replaced with fresh DMEM supplemented with 3% fetal bovine serum. After 4
days if incubation at 37°C wells were analyzed by light microscopy for CPE. The
resulting TCID50 values were calculated using the Reed-Muench method.
rVSV pathogenesis studies:

Syrian Golden hamsters (female, 4-6 weeks of age; Charles River) were
anesthetized and inoculated intraperitoneally (i.p.) with either culture medium
(DMEM) (Mock control) or 1x10^5 plaque forming units (pfu) of the different
rVSV vectors [rVSV∆G-ANDVgpc, rVSV∆G-ZEBOVgp, rVSV∆G-ANDVgpcZEBOVgp, rVSV∆G-ZEBOVgp-ANDVgpc, and VSV-wt] (8 animals per group).
Four animals per group were euthanized on day 2 post infection for collection of
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blood and tissues (e.g., spleen, liver, lung, kidney, brain) to determine viral
growth. The remaining animals (4 hamsters per group) were monitored for
disease progression until 14 days post-infection.
Vaccine efficacy studies:

Syrian Golden hamsters (female, 5-6 weeks of age, Charles River) were
challenged i.p. with a lethal dose of ANDV (200 focus forming units (ffu))
following vaccination or prior to treatment with rVSV vectors (1x10^5 pfu) by the
i.p. or intranasal (i.n.) route. Three animals per group (9 animals in total) were
euthanized on day 8 post-infection and blood and organ samples were collected
for virology. The remaining six animals per group were monitored for survival for
up to 40 days post challenge. For the post-exposure experiment a group of
DMEM alone treated hamsters was included as a negative control group.
Ethics and safety:

Animal studies were approved by the Institutional Animal Care and Use
Committee (IACUC) at Rocky Mountain Laboratories (RML). RML is an American
Association for Accreditation of Laboratory Animal Care (AAALAC) approved
facility. This study was performed in accordance with the recommendations
described in the Guide for the Care and Use of Laboratory Animals of the
National Institute of Health, the Office of Animal Welfare, and the United States
Department of Agriculture. Trained personnel carried out all procedures under
isoflurane anesthesia. The Institutional Biosafety Committee (IBC) at RML
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approved all standard operating protocols (SOPs) for work with infectious rVSV
and ANDV.
Statistical analysis:

Group numbers were selected to achieve a statistical significance with a
minimum statistical power of 80%. All tests were one-tail tests at 95% confidence
intervals and took into account the possibility of having unexpected survivors or
mortality in the treated or control groups (www.dssresearch.com).
Results
rVSV rescue:
The bivalent vaccine vector rVSVΔG-ZEBOVgp-ANDVgpc was rescued in
this study using the rVSV reverse genetics system as previously established
(Lawson et al. 1995; Garbutt et al. 2004). For this, the ZEBOVgp and ANDVgpc
open reading frames were amplified and cloned into the pATX plasmid
downstream of the M gene in the first (bp 3093-31625'; MluI and 3' AvrII
restriction sites) and second cloning positions (bp 3217-3231; 5' SalI and a 3'
NheI restriction sites) (Figure 3-1A). The resulting genome plasmid pATXrVSVΔG-ZEBOVgp-ANDVgpc was sequence-confirmed and used to rescue the
corresponding rVSV on a mixture of Vero and 293 cells. Cell cultures exhibited
CPE after 12 to 14 days post-transfection indicating successful rescue of
rVSVΔG-ZEBOVgp-ANDVgpc. Further confirmation was obtained by RT-PCRamplification of the ZEBOVgp and ANDVgpc open reading frames (Figure 1B)
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and by immunoblot using ZEBOVgp and ANDVgpc-specific antibodies on
material derived from cell culture supernatants (Figure 3-1C). A virus seed
stock was prepared by infecting Vero cells yielding a titer of 4x10^6 plaque
forming units (pfu) as determined by standard plaque assay. The seed stock was
sequenced for final confirmation to exclude the appearance of mutations during
rescue and cell culture passage.
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Figure 3-1: Rescue and confirmation of gene expression of rVSV∆G-ZEBOVgpANDVgpc.
(A) rVSV vectors that express either monovalent [ANDV glycoprotein precursor
(rVSV∆G-ANDVgpc) or Zaire ebolavirus glycoprotein (rVSV∆G-ZEBOVgp)] or
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bivalent (ANDV and ZEBOV glycoproteins; rVSV∆G-ZEBOVgp-ANDVgpc;
rVSV∆G-ANDVgpc-ZEBOVgp) immunogens in place of the native VSV
glycoprotein (VSVwt). (B) RT-PCR amplification of a part of the ZEBOVgp and
ANDVgpc open reading frames from rescued rVSV∆G-ZEBOVgp-ANDVgpc.
(C) Immunoblot using ZEBOVgp and ANDVgpc-specific antibodies on material
derived from cell culture supernatants infected with rVSV∆G-ZEBOVgpANDVgpc.
rVSVs are attenuated in vitro:
As our in vivo vaccine efficacy model is the Syrian Golden hamster, in
vitro testing was started in BHK cells. For this, BHK-21 cells were infected with
rVSVΔG-ZEBOVgp-ANDVgpc, rVSVΔG-ANDVgpc-ZEBOVgp, rVSVΔGZEBOVgp, rVSVΔG-ANDVgpc, or VSVwt at an MOI of 0.001 and supernatants
were collected over the course of 65 hours. VSVwt replicated to the highest titers
at all time points of the experiments with >4 log differences to any rVSV within
the first 24 hours (Figure 3-2A). Up to 24 hours post infection the rVSVs showed
minor differences in replication kinetics with the bivalent vector rVSVΔGANDVgpc-ZEBOVgp displaying the lowest replication rate. After 24 hours, all of
the rVSVs showed comparable virus growth kinetics reaching similar endpoint
titers at 65 hours post infection, about 1 log lower compared to VSVwt (Figure 32A). Virus growth kinetics for all rVSVs were also performed in Vero cells in
comparison to VSVwt resulting in similar replication kinetics (data not shown).
Altogether, the introduction of the foreign glycoprotein genes into the rVSV∆G
genome resulted in in vitro attenuation of the resulting vectors without major
differences between monovalent and bivalent vectors.
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Figure 3-2: rVSVs are attenuated in cell culture and in the hamster disease
model compared to VSVwt.
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(A) BHK-21 cells were infected with rVSVΔG-ZEBOVgp-ANDVgpc, rVSVΔGANDVgpc-ZEBOVgp, rVSVΔG-ZEBOVgp, rVSVΔG-ANDVgpc, or VSVwt at an
MOI of 0.001 and supernatants were collected over the course of 65 hours.
Supernatants were analyzed using a TCID50 assay. (B) Hamsters (groups of 8
animals) were inoculated i.p. with a single dose of rVSV∆G-ANDVgpc,
rVSV∆G-ZEBOVgp, rVSV∆G-ZEBOVgp-ANDVgpc, rVSV∆G-ANDVgpcZEBOVgp or VSVwt (10^5 PFU/animal). Blood and tissue samples (brain, liver,
lung, kidney, and spleen) were taken from 4 hamsters in each group 2 days after
inoculation and infectious titers were analyzed using a TCID50 assay. DMEMinoculated animals served as non-inoculated controls. (C) The remaining 4
animals of each group were monitored for survival over the course of 14 days.
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rVSV vectors are in vivo attenuated:
Syrian Golden hamsters (groups of 8 animals) were inoculated i.p. with a
single dose of rVSV∆G-ANDVgpc, rVSV∆G-ZEBOVgp, rVSV∆G-ZEBOVgpANDVgpc, rVSV∆G-ANDVgpc-ZEBOVgp and VSVwt (10^5 PFU/animal). A
DMEM-inoculated animals served as non-inoculated controls. The inoculation
with VSVwt at this dose resulted in lethality of 50%. In contrast, animals in all
other rVSV inoculated groups showed no or very limited disease signs
(temporary minor weight loss of up to 3% over the first three days) and survived
the inoculation (Figure 3-2C). To assess rVSV replication, blood and tissue
samples (brain, liver, lung, kidney, and spleen) were taken from 4 hamsters in
each group 2 days after inoculation and infectious titers were analyzed using a
TCID50 assay (Figure 3-2B). VSVwt inoculated animals were positive in all
tissues tested. To assess survival after rVSV inoculation the remaining 4
hamsters in each group were monitored for symptoms of disease such as weight
loss, ruffled fur, reduced movement, and others for 14 consecutive days or until
clinical signs indicated a humane endpoint (Figure 3-2C). Of all rVSV groups only
animals inoculated with rVSV∆G-ZEBOVgp were clearly positive for viral
infectivity with organ titers similar to VSVwt inoculated animals. Organ titers
around the detection limit were found in hamsters inoculated with rVSV∆GZEBOVgp-ANDVgpc, whereas no viral infectivity was found in organs or blood of
animals inoculated with rVSV∆G-ANDVgpc or rVSV∆G-ANDVgpc-ZEBOVgp
(Figure 3-2B). Overall, all rVSV vectors are attenuated in the hamster disease
model compared to VSVwt warranting vaccine efficacy studies in this model.
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rVSV vectors protect against ANDV challenge when administered preexposure.
For pre-exposure efficacy testing of the rVSV vectors, hamsters (group of 9
animals) were immunized i.p. or i.n. with a single dose of 10^5 PFU 28 days
before lethal ANDV challenge (200 FFU/animal). Three animals of each group
were euthanized on day 8 post challenge for lung (main target organ for ANDV
infection) and blood titration. All animals remained clinically asymptomatic during
the vaccination period indicating a lack of adverse effects to immunization with
the rVSV vectors in this animal species. The animals immunized with the
monovalent non-specific rVSVΔG-ZEBOVgp vector, expressing the ZEBOV
glycoprotein were, as expected, unprotected and succumbed to infection
between days 7 to 11 post ANDV challenge (Table 3-1). Animals immunized with
the monovalent specific rVSVΔG-ANDVgpc vector were expected to be protected
and showed 100% (i.n. vaccination) and 83% (i.p. vaccination) survival. Animals
immunized with the two bivalent vectors, rVSVΔG-ZEBOVgp-ANDVgpc and
rVSVΔG-ANDVgpc-ZEBOVgp were completely protected independent of route of
vaccination. The survival data is supported by organ and blood titers as shown in
Figure 3-3A.
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Table 3-1: Bivalent rVSV∆G-ZEBOVgp-ANDVgpc offers better post-exposure
protection than previous bivalent and monovalent constructs.
Hamsters (group of 6 animals) were immunized i.p. or i.n. with a single dose of
10^5 PFU before (-28 days and -3 days pre-exposure) or after (days +1, +3 and
+5 post-exposure) lethal ANDV challenge (200 FFU/animal). Animals were
monitored for survival up to 40 days post challenge.
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In order to address the potential for rapid immunization we next
immunized animals with a single dose of 10^5 PFU 3 days prior to lethal ANDV
challenge (200 FFU/animal). Animals immunized by the i.n. route with the
monovalent specific rVSVΔG-ANDVgpc vector were only partially protected
(33%), whereas animals immunized i.p. showed full protection (100%) (Table 1).
Interestingly, survival increased from none to 33% in the group that was
immunized i.p. with the non-specific monovalent rVSVΔG-ZEBOVgp vector
(Table 3-1). All animals immunized by either route with the two bivalent vectors
were fully protected against lethal ANDV challenge. As with the day 28
immunization, the survival data is supported by organ and blood titers shown in
Figure 3-3B.
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Figure 3-3: Blood and lung tissue data support survival data in preexposure treatment with rVSVs.
Hamsters (group of 9 animals) were immunized i.p. or i.n. with a single dose of
10^5 PFU before (-28 days and -3 days) lethal ANDV challenge (200
FFU/animal). (A) lung tissue and blood was taken from 3 animals of each group
vaccinated 28 days prior to challenge and analyzed for viral replication using RTPCR. (B) Lung tissue and blood were taken from 3 animals of each group
vaccinated 3 days prior to challenge and analyzed for viral replication using RTPCR.
rVSV vectors protect against ANDV challenge when administered shortly after
exposure:
For post-exposure efficacy testing of the rVSV vectors, hamsters (group of
9 animals) were immunized i.p. or i.n. with a single dose of 10^5 PFU on days
+1, +3 and +5 after lethal ANDV challenge (200 FFU/animal). As with the preexposure study, three animals of each group were euthanized on day 8 post
challenge for organ (lung) and blood titration. None of the animals immunized i.p.
or i.n. on day 5 or immunized i.n. on day 3 post ANDV challenge were protected.
Disease progression was almost identical to DMEM-treated controls resulting in
death (Table 3-1). In contrast, all hamsters in the groups immunized i.p. 1 day
post ANDV challenge with the two bivalent vectors as well as the non-specific
monovalent rVSVΔG-ZEBOVgp vector survived ANDV challenge, whereas
surprisingly survival was only 33% in the group immunized i.p. with the
monovalent rVSVΔG-ANDVgpc vector (Table 3-1). The i.n. route of immunization
was less efficient but showed a similar trend with only the hamsters in the
rVSVΔG-ZEBOVgp-ANDVgpc group showing 100% survival, followed by 83%
and 50% survival when immunized i.n. with rVSVΔG-ZEBOVgp and rVSVΔG-
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ANDVgpc-ZEBOVgp, respectively. Again, the monovalent specific rVSVΔGANDVgpc vector did not perform well with no survival after single-shot i.n.
immunization. A similar result was observed with i.p. immunization on day 3
post ANDV challenge. The bivalent rVSVΔG-ZEBOVgp-ANDVgpc vector
performed best with 83% survival followed by the rVSVΔG-ZEBOVgp vector with
67% survival. The other two vectors did not provide any protection from disease
and death. Infectivity data on lung tissue and blood confirmed ANDV infection of
the animals, but did not show significant distinction among the vaccine groups
(Figure 3-4).
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Figure 3-4: Post-exposure treatment with rVSVs does not prevent ANDV
Infection.
Hamsters (group of 9 animals) were immunized i.p. or i.n. with a single dose of
10^5 PFU after lethal ANDV challenge (200 FFU/animal). (A) Three animals of
each group inoculated 1 day after challenge were euthanized on day 8 post
challenge for organ (lung) and blood titration using RT-PCR. This was repeated
for groups inoculated 3 days (B) and 5 days (C) after challenge.
Overall, best performance in post-exposure vaccination was achieved
with the two bivalent vectors with rVSVΔG-ZEBOVgp-ANDVgpc being superior in
efficacy. Interestingly, the monovalent non-specific rVSVΔG-ZEBOVgp vector
was almost as efficacious against ANDV challenge if administered shortly after
post-exposure. Surprisingly, the monovalent specific rVSVΔG-ANDVgpc vector
performed extremely poorly in post-exposure vaccination. The i.p. immunization
route was superior over the i.n. route for post-exposure vaccination.
Discussion
Although the annual cases of ANDV remain low in South America when
compared to incidences of Old World strains in Europe and Asia, the high
lethality rate and the potential for human-to-human transmission illustrates that a
vaccine and other treatments for the disease need to be developed.
Historically, rVSV has been used extensively as a laboratory tool for
studying virus and cell biology, but more recently its potential as a therapeutic
and vaccine tool has been realized. Here we have constructed and rescued a
bivalent rVSV vaccine vector that expresses the glycoproteins from ZEBOV and
ANDV in place of the native VSV glycoprotein. The rationale for the bivalent
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vaccine vector was based on evidence that the ZEBOVgp targets the vaccine
vectors to important immune cells strongly enhancing innate immune
responses (Prescott et al. 2015). For this study we used the Syrian hamster
model to test vaccine safety and efficacy. While rVSVwt caused systemic
infection in Syrian hamsters resulting in severe or lethal outcome, the rVSVbased vaccine candidates temporarily replicated in Syrian hamsters without
causing signs of clinical disease. We showed that the rVSV-based vaccine
candidates are attenuated when compared to the VSVwt in hamsters and tissue
culture cells.
The protective efficacy of the rVSV vectors was also tested following
administration prior to or after ANDV challenge in the HPS hamster model in
order to define the most potent candidate vaccine for prophylactic vaccination
and post-exposure treatment. The results indicated that the organization of the
ZEBOV and ANDV genes can alter the protection in the hamster. Importantly, the
efficacy of post-exposure protection was increased by including the ZEBOVgp
upstream of the ANDVgpc immunogen in the bivalent rVSV∆G-ZEBOVgpANDVgpc. This may be due to increased ZEBOVgp production, expression or
presentation to the innate immune system.
Although ANDV results in systemic infection in hamsters, the lungs are the
primary site of viral replication and the only organ which develops pathological
abnormalities during the course of disease (Safronetz et al. 2011). We correctly
expected that, similar to i.p. immunization, administration of the ANDVgpc
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containing rVSV vaccines via the i.n. route would provide 100% protection
when given 28 days pre-exposure. While we hypothesized that i.n.
immunization would provide increase post-exposure protection by eliciting a
strong innate immune response directly in the lungs of hamsters, the results
showed a trend that indicated that the i.p. route was more effective and that the
efficacy of mucosal immunization post-challenge may not offer the same
protection as a systemic i.p. inoculation.
The results of these experiments further defined the protective efficacy of
the recombinant rVSV vaccine candidates in the Syrian hamster model when
challenged with a lethal dose of ANDV. Importantly, using the novel rVSV vectors
we were able to demonstrate an increase in efficacy of post-exposure protection
in the lethal hamsters model of HPS (Brown et al. 2011; Tsuda et al. 2011).
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CHAPTER 4 CONCLUSIONS
Summary

Although the annual cases of ANDV remains low in South America, when
compared to incidences of Old World strains of Europe and Asia, the high
lethality rate and the potential for human-to-human transmission illustrates that a
vaccine and other treatments for the disease need to be developed. This
dissertation describes the development of a rVSV based vaccine platform that is
effective in protecting Syrian hamsters in peri-exposure challenge with a lethal
dose of ANDV. In addition, constructs that contain the ANDVgpc are also useful
when used as a conventional vaccine 28 days before challenge.
In summary, these data have shown that rVSV presents an efficient
system for tailoring specific vaccines for ANDV. First, chapter 2 investigates the
use of STAT1 KO mice as an animal model to test the tolerance of rVSV
constructs as vaccine vectors. The results of chapter 2 have shown that mice
lacking an innate immune response involving interferon alpha, beta, and gamma
do not comprise an animal model which is suited for testing rVSV vaccine
vectors. Specifically, the rVSVs cause severe disease in the
immunocompromised mouse model therefore disqualifying it as a useful model in
my studies. Second, chapter 3 describes the successful design and rescue of a
bivalent rVSV that expresses both ANDV and ZEBOV glycoproteins in place of
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the deleted VSV glycoprotein. The results in chapter 3 describe how the
insertion of glycoproteins from ZEBOV and ANDV effectively attenuates the
pathogenicity of the rVSV vector thereby reducing negative symptoms in the
hamster model while still allowing enough replication for the rVSVs to induce a
robust and protective immune response after only one inoculating dose. The data
support that the rVSV∆G-ZEBOVgp-ANDVgpc vaccine vector was more
protective than both monovalent vectors and the bivalent vector rVSV∆GANDVgpc-ZEBOVgp. The new bivalent vector rVSV∆G-ZEBOVgp-ANDVgpc
was able to protect 83% of animals with a single i.p. inoculation 3 days after a
lethal ANDV challenge. This surpasses all other previously developed rVSV
vaccines designed for hantavirus vaccination in the Syrian hamster model. The
protections studies show that, for overall survival, the bivalent vectors with both
the ZEBOV and ANDV glycoprotein inserts are very effective. It may be shown in
future studies that look more closely at the specific immune response that the
ZEBOVgp is effective at initiating a broadly protective short term innate response
while the presence of the ANDVgpc allows the formation/establishment of a long
lived and specific adaptive response in a single dose immunization. The survival
results of these protection studies also suggest that the placement of the
glycoprotein gene in the rVSV genome can play a significant role in the survival
outcome of lethally inoculated animals. In general, having the ZEBOVgp gene in
the most upstream cloning position was more protective in the post-exposure
vaccination when animals were challenged with a lethal dose of ANDV in both
the monovalent and bivalent genome configurations. The data showing the viral
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load on blood and lung from lethally inoculated animals is interesting but
difficult to make any conclusions about without more in-depth experiments that
examine the mechanism of the immune response. It may indicate that survival
may not be as dependent on the ability of the rVSV vector to induce an immune
state that reduces the overall viral load (in post exposure studies) but may be
another mechanism that is more influential in survival. This may be due to the
vector's ability to modulate the immune response to reduce pathological and
destructive immune responses. One of the limitations of these studies is the lack
of established and commercially available reagents to examine the mechanism of
the hamster immune response but, as the hamster model sees increased use as
a disease model these materials will become more available.
In light that rVSV constructs, which contain an unrelated antigen to the
hantavirus family, can provide protection against a heterologous virus challenge
is striking. It has been hypothesized that rVSV is able to produce a very robust,
non-specific, innate response which serves to suppress the levels of the
challenge virus until the adaptive immune response, which would otherwise be
too slow, establishes itself enough to clear the virus.
Significance

These studies have the potential to further the understanding of vaccine
action and may provide insights that lead to the development of better vaccines
that are fast acting, are effective without multiple boosts and can offer protection
in extremely short durations before exposure. Such scenarios could be critical in
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an ANDV outbreak where human-to-human transmission has been
documented, as well as, post exposure treatments that could arise in the field
or in laboratory conditions. The ability to administer a vaccination that can
protect in the extreme short term and after exposure have proved to be extremely
useful. Examples of this can be found in the current Rabies vaccine and the use
of the experimental rVSV-ZEBOV vaccine in the recent West African Ebola
outbreak where a VSV-based vaccine was successfully used in emergency ring
vaccination. (Henao-Restrepo et al. 2016) (Dean et al. 2015). I anticipate that this
research will provide useful insight that allows the future development of these
types of vaccines and reduce the number of deaths that result from these ever
increasing and dangerous zoonotic pathogens as our world becomes less
constrained by borders and more mobile.
Future Directions

In conclusion of my research project, I have gathered data that will
generate renewed and lasting interest in the phenomenon that allows the
ZEBOVgp to protect against unrelated viral diseases when used as a periexposure vaccination. In particular it will be interesting what insights will be
discovered regarding the mechanism of the immune response as newer more
powerful tools become available. For future directions the mechanism of the
immune responses responsible for the peri-exposure protection should be
defined and evaluated. Unfortunately, many of the advanced tools and reagents
are still underdeveloped or unavailable to study this in the hamster model.
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Hopefully my study will further the use of the Syrian hamster model in the
Hantavirus field and initiate more commercial reagent development. It is
thought that the inclusion of the ZEBOVgp in the first cloning position of the
rVSV genome is able to induce a rapid innate immune response that enhances
the effect of the vaccine. Unfortunately, I was not able to explore the immune
response to determine the mechanism of this short-term peri-exposure
protection. However, future work towards this goal should be pursued. Defining
the immunological mechanism would be an important milestone and would be
valuable as it could be applied broadly to direct future vaccine development.
With the recent publication of the hamster genome/transcriptome it could
be valuable to explore methods that use deep sequencing to look at changes in
transcription profiles in hamsters and used to look at differences in the
transcriptomes / transcriptional changes of animals that get different vaccines to
identify differential gene expression that could influence the immune responses
in the hamster model. This could provide key insights to investigate the idea that
ZEBOVgp targets the vaccine vectors to important immune cells strongly
enhancing innate and adaptive immune responses and, thus improve protective
efficacy which could, in turn, allow for further optimization of the vectors (and
maybe unrelated vaccine platforms) to increase the protective efficacy and/or
extend the window of time in which the vaccine could be effectively administered.
Second, since the protection studies were performed with only 6 animals
per group these experiments should be reproduced using larger group sizes to
enhance the confidence in the improvement of the rVSVΔG-ZEBOVgp-ANDVgpc
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over the other bivalent and monovalent rVSVs. In addition, the results should
be confirmed in a second animal model if one is developed. Preferentially, the
second animal model would be a nonhuman primate model to evaluate safety
and immunology before advancing to human trials
Overall this study has greatly advanced the understanding that the
inclusion of a second glycoprotein from a completely unrelated virus (ZEBOVgp)
can stimulate the immune system in such a way that there is an enhancement of
the post-exposure protection of hamsters from a ANDV challenge. Finally, it may
also be important in answering questions about the overall use of vaccines and
other therapeutics that are used in post-exposure protection from other viral
illnesses.
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